This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
by Ekta Bagri
Praxis Precision Medicines, Inc. (PRAX) and Viking Therapeutics, Inc. (VKTX) gain from positive study updates.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA
by Zacks Equity Research
Regeneron's (REGN) efforts to expand its oncology portfolio get a hit as the FDA refuses to approve the lymphoma drug odronextamab.
Top Research Reports for JPMorgan Chase, Merck & SAP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Merck & Co., Inc. (MRK) and SAP SE (SAP).
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
by Zacks Equity Research
Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
by Zacks Equity Research
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?
by Zacks Equity Research
Cardiff Oncology (CRDF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up
by Zacks Equity Research
NewAmsterdam (NAMS) gains on the initiation of a phase III study evaluating fixed-dose combination of obicetrapib and ezetimibe in patients with HeFH and/or ASCVD.
Regeneron (REGN) Gets FDA Nod for Praluent Label Extension
by Zacks Equity Research
Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
by Zacks Equity Research
ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.
Why Is Exelixis (EXEL) Up 10.9% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
EXEL vs. REGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
EXEL vs. REGN: Which Stock Is the Better Value Option?
Bayer (BAYRY) Q4 Earnings Top, Crop Science Unit Drives Revenues
by Zacks Equity Research
Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products.
Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update
by Zacks Equity Research
Intellia's (NTLA) earnings beat estimates in the fourth quarter while the company reports negative revenues. Management provides developmental and regulatory updates on its key pipeline candidates.
The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron
by Zacks Equity Research
Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron are included in this Analyst Blog.
Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates
by Zacks Equity Research
Earnings from Moderna (MRNA) and pipeline update from RAPT are in focus in the biotech sector.
Roche's (RHHBY) Xolair Gets Approval for Food Allergies
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.
Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%
by Zacks Equity Research
Alnylam (ALNY) reports mixed fourth-quarter 2023 results, as earnings beat estimates, while revenues miss the same. The stock of the company falls 10%.
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
EXEL or REGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. REGN: Which Stock Is the Better Value Option?
Regeneron (REGN) Q4 Earnings & Sales Top, Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) beats earnings and sales estimates in fourth-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, continue to fall.
Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Regeneron (REGN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 13.71% and 5.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down
by Zacks Equity Research
Roche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in COVID-19-test sales. Currency rate fluctuations also impact results.
Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down
by Zacks Equity Research
Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.